156 related articles for article (PubMed ID: 24566708)
1. Donor-derived CD4(+)/CCR7(+) T-cell partial selective depletion does not alter acquired anti-infective immunity.
Choufi B; Trauet J; Thiant S; Labalette M; Yakoub-Agha I
Bone Marrow Transplant; 2014 May; 49(5):611-5. PubMed ID: 24566708
[TBL] [Abstract][Full Text] [Related]
2. Immunomagnetic selective donor-derived CD4
Varlet P; Rogeau S; Trauet J; Demaret J; Labalette M
Curr Res Transl Med; 2019 Feb; 67(1):1-7. PubMed ID: 30665880
[TBL] [Abstract][Full Text] [Related]
3. [The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+/CCR7+ T cell subsets and acute graft-versus-host disease].
Choufi B; Thiant S; Trauet J; Cliquennois M; Cherrel M; Boulanger F; Coiteux V; Magro L; Labalette M; Yakoub-Agha I
Pathol Biol (Paris); 2014 Jun; 62(3):123-8. PubMed ID: 24906571
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
7. A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy.
Yakoub-Agha I; Saule P; Depil S; Micol JB; Grutzmacher C; Boulanger-Villard F; Bauters F; Jouet JP; Dessaint JP; Labalette M
Leukemia; 2006 Sep; 20(9):1557-65. PubMed ID: 16826221
[TBL] [Abstract][Full Text] [Related]
8. Donor-derived CD4
Varlet P; Alsuliman T; Trauet J; Demaret J; Labalette M; Yakoub-Agha I
Bone Marrow Transplant; 2019 Oct; 54(10):1686-1693. PubMed ID: 30890769
[TBL] [Abstract][Full Text] [Related]
9. A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD.
Portero-Sainz I; Gómez-García de Soria V; Cuesta-Mateos C; Fernández-Arandojo C; Vega-Piris L; Royg M; Colom-Fernández B; Marcos-Jiménez A; Somovilla-Crespo B; Ramírez-Mengíbar A; López-Huete V; de Rosendo-Serrano A; Kreutzman A; Muñoz-Calleja C
Bone Marrow Transplant; 2017 May; 52(5):745-752. PubMed ID: 28112745
[TBL] [Abstract][Full Text] [Related]
10. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation.
Godfrey WR; Krampf MR; Taylor PA; Blazar BR
Blood; 2004 Feb; 103(3):1158-65. PubMed ID: 14525783
[TBL] [Abstract][Full Text] [Related]
12. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.
Solomon SR; Mielke S; Savani BN; Montero A; Wisch L; Childs R; Hensel N; Schindler J; Ghetie V; Leitman SF; Mai T; Carter CS; Kurlander R; Read EJ; Vitetta ES; Barrett AJ
Blood; 2005 Aug; 106(3):1123-9. PubMed ID: 15817673
[TBL] [Abstract][Full Text] [Related]
13. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
14. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
15. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
16. Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras.
de Jager SC; Canté-Barrett K; Bot I; Husberg C; van Puijvelde GH; van Santbrink PJ; Yndestad A; van den Oever JM; Kuiper J; van Berkel TJ; Lipp M; Zwaginga JJ; Fibbe WE; Aukrust P; Biessen EA
Transplantation; 2009 Sep; 88(5):631-9. PubMed ID: 19741459
[TBL] [Abstract][Full Text] [Related]
17. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis.
Teschner D; Distler E; Wehler D; Frey M; Marandiuc D; Langeveld K; Theobald M; Thomas S; Herr W
Bone Marrow Transplant; 2014 Jan; 49(1):138-44. PubMed ID: 23933765
[TBL] [Abstract][Full Text] [Related]
18. Donor bone marrow-derived T cells inhibit GVHD induced by donor lymphocyte infusion in established mixed allogeneic hematopoietic chimeras.
Wang H; Yang Y; Wang G; Wang S; Yeap BY; Sykes M; Yang YG
PLoS One; 2012; 7(10):e47120. PubMed ID: 23077554
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics.
Yakoub-Agha I; Saule P; Depil S; Grutzmacher C; Boulanger F; Magro L; Jouet JP; Dessaint JP; Labalette M
Exp Hematol; 2007 Jun; 35(6):861-71. PubMed ID: 17533040
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
